Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-12-23
Buyer: Oslo Universitetssykehus HF (hovedenhet)
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33100000
Estimated value: 5500000 NOK
Award criteria: The most economic tender

Technical requirements: Institutt for farmakologi ved Oslo universitetssykehus [the Institute for Pharmacology at Oslo University Hospital] intends to procure an instrument that is suitable for efficient and flexible DNA gene variant and methylate analyses for pharmacogenetic purposes. The instrument must be capable of operating standard and specially designed kit panels, it must be flexible with respect to set constructions (i.e. combinations of gene variants) and it must be integrated with user-friendly software for data collection, interpretation and reporting. The instrument must have the capacity to run a minimum of 15 gene variants in a minimum of 3 different genes (including copy number variations) in ten clinical trials with a maximum processing time of 10 hours. The expected number of analyses per year will be 1 0000 to 5 000 analyses.
Institutt for farmakologi ved Oslo universitetssykehus [the Institute for Pharmacology at Oslo University Hospital] intends to procure an instrument that is suitable for efficient and flexible DNA gene variant and methylate analyses for pharmacogenetic purposes. The instrument must be capable of operating standard and specially designed kit panels, it must be flexible with respect to set constructions (i.e. combinations of gene variants) and it must be integrated with user-friendly software for data collection, interpretation and reporting. The instrument must have the capacity to run a minimum of 15 gene variants in a minimum of 3 different genes (including copy number variations) in ten clinical trials with a maximum processing time of 10 hours. The anticipated number of analyses per year will be 1 000 to 5 000 analyses. The system will offer the complete analytical repertoire that is listed in the attached table 1. The pharmacological genotype panels must be available as standard or custom panels and validated.
The system must five the possibility to design custom panels including selected genes and variants from table 1, with flexibility with respect to combinations.
The system must be able to provide quantitative assessment of changes in the degree of DNA methylation (down to 5-10 % difference).
The system must have a high capacity for analytical throughput and short turnover time from extraction of DNA to reportable result (including testing of a minimum 15 clinical relevant gene variants in CYP2C19, CYP2C9 and CYP2D6, including CYP2D6 copy number variations, in ten patients with a maximum processing time of 10 hours.
The system must have user-friendly software for data collection, interpretation of results and converting to communicable genotype descriptions and clinically useful genotype annotations. The possibility for simplified export of the results via LIMS (laboratory information management system) is crucial.
Software for assay design/development must be delivered. For example, correct analysis of a control sample.
The system must offer the complete analytical repertoire that is listed in the attached table 1. The pharmacological genotype panels must be available as standard or custom panels and validated.
The system must have the possibility to design custom panels including selected genes and variants from table 1, with flexibility with respect to combinations.
The system must be able to provide quantitative assessment of changes in the degree of DNA methylation (down to 5-10 % difference).
The system must have a high capacity for analytical throughput and short turnover time from extraction of DNA to reportable result (including testing of a minimum 15 clinical relevant gene variants in CYP2C19, CYP2C9 and CYP2D6, including CYP2D6 copy number variations, in ten patients with a maximum processing time of 10 hours.
The system must have user-friendly software for data collection, interpretation of results and converting to communicable genotype descriptions and clinically useful genotype annotations. The possibility for simplified export of the results via LIMS (laboratory information management system) is crucial.
Software for assay design/development must be delivered. For example, correct analysis of a control test. For technical reasons, it is believed that Agena Bioscience GmBH is the only supplier who can deliver in accordance with the requirements. The voluntary ex-ante transparency notice is pursuant to the public procurement Regulations § 21-5. The terms in PPR § 13-4 (2) and 13-1 (5) are considered fulfilled, as well as the value of the full service contract and a contract for consumables for the lifetime of the equipment.


Winner: Agena Bioscience GmBH
Award value: 5500000